GoAI
Get started
Pro-Dex, Inc. logo

Pro-Dex, Inc.

PDEX

NASDAQHealthcareMedical - Instruments & Supplies

Open in GoAI

Previous close

$65.67

−$0.64 · -0.97%

Aug 21, 4:00 PM ET

Pre-market

$65.21

−$0.46 · -0.70%

Aug 24, 7:09 AM ET

PDEX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

99

Deep Value

Momentum

79

Gaining

Sentiment

53

Mixed

Risk resilience

60

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Pro-Dex, Inc. focuses on the development and manufacturing of advanced motorized surgical instruments. These sophisticated tools are supplied globally to original equipment manufacturers (OEMs) in the medical device sector. Their product portfolio features versatile, autoclavable (sterilization-friendly) surgical drivers and shavers, available in both battery-powered and electric models, often equipped with multi-functional capabilities. These instruments are primarily employed in orthopedic, thoracic, and craniomaxillofacial surgical procedures. Beyond its core manufacturing, Pro-Dex also offers expert consulting services, covering engineering, quality assurance, and regulatory compliance. Furthermore, the company manufactures and distributes rotary air motors to various industrial clients. Founded in 1978, Pro-Dex, Inc. maintains its corporate headquarters in Irvine, California.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Richard Lee Van Kirk Jr.
Listed since
Aug 7, 1986
Employees
180

Market position

Day range

Current $65.67

52-week range

Current $65.67

Open
$66.02
Previous close
$66.31
Volume
33.04K
0.5× average
Average volume
65.9K
Average daily volume
Market cap
209.67M USD
Beta
0.05
Market reference 1
50-day average
$61.7914
+6.28% above average
200-day average
$49.9625
+31.44% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
159.64M USD
P/E (TTM)
17.75×
P/B (TTM)
4.65×
P/S (TTM)
2.81×
EV / EBITDA
11.3×
Earnings yield
6.26%
Free cash flow yield
-2.04%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
27.78%
Operating margin
14.48%
Net margin
16.08%
Return on equity
24.51%
Return on assets
14.67%
Return on invested capital
14.96%

Financial health

Debt / equity
0.45×
Current ratio
3.23×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends34%23%12%1%Gross margin, FY2021: 31.24%Gross margin, FY2022: 31.24%Gross margin, FY2023: 27.66%Gross margin, FY2024: 27.02%Gross margin, FY2025: 29.30%Operating margin, FY2021: 12.19%Operating margin, FY2022: 12.19%Operating margin, FY2023: 12.50%Operating margin, FY2024: 13.32%Operating margin, FY2025: 16.05%Net margin, FY2021: 10.88%Net margin, FY2022: 10.88%Net margin, FY2023: 15.35%Net margin, FY2024: 3.95%Net margin, FY2025: 13.48%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 31.24%. Gross margin FY2022 31.24%. Gross margin FY2023 27.66%. Gross margin FY2024 27.02%. Gross margin FY2025 29.30%. Operating margin FY2021 12.19%. Operating margin FY2022 12.19%. Operating margin FY2023 12.50%. Operating margin FY2024 13.32%. Operating margin FY2025 16.05%. Net margin FY2021 10.88%. Net margin FY2022 10.88%. Net margin FY2023 15.35%. Net margin FY2024 3.95%. Net margin FY2025 13.48%.

Income trends

Revenue

66.59M USD+23.68%

Operating income

10.69M USD+49.02%

Net income

8.98M USD+322.10%
Income trends across reported periods73.04M USD47.25M USD21.47M USD−4.32M USDRevenue, FY2021: 42.04M USDRevenue, FY2022: 42.04M USDRevenue, FY2023: 46.09M USDRevenue, FY2024: 53.84M USDRevenue, FY2025: 66.59M USDOperating income, FY2021: 5.12M USDOperating income, FY2022: 5.12M USDOperating income, FY2023: 5.76M USDOperating income, FY2024: 7.17M USDOperating income, FY2025: 10.69M USDNet income, FY2021: 4.57M USDNet income, FY2022: 4.57M USDNet income, FY2023: 7.07M USDNet income, FY2024: 2.13M USDNet income, FY2025: 8.98M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 42.04M USD. Revenue FY2022 42.04M USD. Revenue FY2023 46.09M USD. Revenue FY2024 53.84M USD. Revenue FY2025 66.59M USD. Operating income FY2021 5.12M USD. Operating income FY2022 5.12M USD. Operating income FY2023 5.76M USD. Operating income FY2024 7.17M USD. Operating income FY2025 10.69M USD. Net income FY2021 4.57M USD. Net income FY2022 4.57M USD. Net income FY2023 7.07M USD. Net income FY2024 2.13M USD. Net income FY2025 8.98M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue66.59M USD53.84M USD46.09M USD42.04M USD42.04M USD
Cost of goods sold47.08M USD39.29M USD33.34M USD28.91M USD28.91M USD
Gross profit19.51M USD14.55M USD12.75M USD13.13M USD13.13M USD
Research and development3.64M USD3.19M USD2.8M USD2.98M USD2.98M USD
Selling, general, and administrative5.19M USD4.19M USD4.18M USD4.99M USD4.99M USD
Operating expenses8.82M USD7.38M USD6.99M USD8.01M USD8.01M USD
Interest income82K USD144K USD294K USD76K USD126K USD
Interest expense829K USD558K USD533K USD464K USD352K USD
Depreciation and amortization1.24M USD1.16M USD857K USD726K USD726K USD
Operating income10.69M USD7.17M USD5.76M USD5.12M USD5.12M USD
Net income8.98M USD2.13M USD7.07M USD4.57M USD4.57M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

1 institution

Corporate actions

Corporate action history

Stock split

Effective Jun 18, 2010

1:3

PDEX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PDEX

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
3.49M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.28M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
1.36M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.22M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
681.7K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
First Trust Dow Jones Select MicroCap Index Fund logoFirst Trust Dow Jones Select MicroCap Index FundFDM
Market value
639.69K
Weight
0.15%
AUM
423.22M USD
Expense ratio
0.65%
Price / 1D
$92.96+0.50%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
512.82K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
469.08K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research PDEX

research.disclaimer